{"algorithm_version": "v0.6.0", "applied_rules": {"base_min_final_score": 68.0, "min_bullish_analyses": 2, "min_confidence": 0.62, "min_final_score": 70.0, "min_liquidity_avg_volume": 750000, "regime": "mixed", "regime_score_delta": 2.0}, "benchmark": "SPY", "catalysts": ["October 12, 2026: Genmab and AbbVie announced FDA approval of EPKINLY (epcoritamab) with rituximab and lenalidomide for earlier-line treatment of follicular lymphoma in the United States. This expands the drug’s addressable market and could support revenue expectations.", "October 7, 2026: Genmab and AbbVie reported statistically significant Phase 3 results for epcoritamab plus R-CHOP in newly diagnosed diffuse large B-cell lymphoma, including a reported 51% reduction in the risk of progression or death. Regulatory discussions are planned.", "Positive Phase 3 trial results for epcoritamab in lymphoma support future growth.", "The FDA just approved EPKINLY for an earlier stage of follicular lymphoma, expanding the drug's potential patient pool and revenue opportunity.", "A Phase 3 trial showed epcoritamab cut the risk of cancer progression or death by 51% in a common form of lymphoma, opening a new regulatory pathway."], "company_name": "Genmab A/S", "conviction": "high", "data_quality": 0.865, "date": "2026-10-12", "favorable_models_count": 3, "final_confidence": 0.7632133709625317, "final_score": 74.71933333333334, "generated_at": "2026-10-12T07:30:00.006489-04:00", "horizon": "intraday", "models_answered": 3, "models_asked": 3, "quantitative_score": 50.34, "reason": null, "regulatory_warning": "This is automated, general-audience analysis published for informational purposes only. It is not a personal recommendation, not a promise of performance, and not an invitation to buy or sell any financial instrument. Every investment can lose value, and past results do not predict future ones.", "risks": ["The stock has already risen about 14% over 20 trading days, so traders may take profits after the recent rally.", "Premarket pricing was slightly lower, and relative volume was only 0.59, suggesting the FDA news may not produce strong immediate buying without higher volume.", "The stock has already seen a strong run-up, increasing the chance of profit-taking.", "Low trading volume may limit upside or cause choppy price action.", "The stock is already up about 14% over the past month, so much of the good news may already be priced in."], "shortfalls": [], "status": "signal", "summary": "The strongest next-session catalyst is the October 12 FDA approval expanding EPKINLY into earlier-line follicular lymphoma treatment. Combined with recent positive Phase 3 lymphoma data and multiple price-target increases, the news flow is bullish. However, the stock’s recent run-up and low relative volume raise the risk of profit-taking or a muted reaction.", "ticker": "GMAB", "timezone": "Europe/Zurich", "watchlist": []}